Literature DB >> 27423642

Primary unclassified sarcoma of the parotid gland: a case of diagnostic and therapeutic challenge.

Panagiotis Saravakos1, Joerg Hartwein2, Afshin Fayyazi3.   

Abstract

Malignant salivary gland sarcomas represent a clinically and histologically diagnostic challenge. Primary unclassified sarcomas of the parotid gland consist a rare salivary gland tumor. We report an unusual case of such a tumor, which occurred in the right parotid gland of a 54-year-old male and presented as an asymptomatic painless mass. The pathologoanatomical examination revealed a rhabdoid large-cell unclassified sarcoma. The patient was treated with superficial parotidectomy and adjuvant radiotherapy. No recurrence was noted in a 10-year follow-up period. Due to the rare occurrence of primary unclassified sarcomas, there is no evidence-based treatment of choice. An optimal approach is best planned in a multidisciplinary setting, taking into consideration the resectability of the tumor, individual patient characteristics, presence of local or distant metastatic activity, local infiltrative behavior and tumor stage. A close follow-up of the patient is strongly recommended.

Entities:  

Keywords:  Head and neck sarcomas; NOS sarcoma; Parotid tumor; Primary unclassified sarcoma; Salivary malignancy

Mesh:

Year:  2016        PMID: 27423642     DOI: 10.1007/s00405-016-4204-1

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  16 in total

1.  The distribution of vimentin and keratin in epithelial and nonepithelial neoplasms. A comprehensive immunohistochemical study on formalin- and alcohol-fixed tumors.

Authors:  N Azumi; H Battifora
Journal:  Am J Clin Pathol       Date:  1987-09       Impact factor: 2.493

2.  SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas.

Authors:  Piergiorgio Modena; Elena Lualdi; Federica Facchinetti; Lisa Galli; Manuel R Teixeira; Silvana Pilotti; Gabriella Sozzi
Journal:  Cancer Res       Date:  2005-05-15       Impact factor: 12.701

3.  Epithelioid sarcoma: a clinicopathologic and immunohistochemical analysis of 106 cases from the French sarcoma group.

Authors:  Laila Chbani; Louis Guillou; Philippe Terrier; Anne Valérie Decouvelaere; Fleur Grégoire; Marie José Terrier-Lacombe; Dominique Ranchère; Yves Marie Robin; Françoise Collin; Paul Fréneaux; Jean-Michel Coindre
Journal:  Am J Clin Pathol       Date:  2009-02       Impact factor: 2.493

Review 4.  Sarcomas of the head and neck region.

Authors:  Thomas D Shellenberger; Erich M Sturgis
Journal:  Curr Oncol Rep       Date:  2009-03       Impact factor: 5.075

Review 5.  Major and minor salivary gland tumors.

Authors:  Marco Guzzo; Laura D Locati; Franz J Prott; Gemma Gatta; Mark McGurk; Lisa Licitra
Journal:  Crit Rev Oncol Hematol       Date:  2009-11-24       Impact factor: 6.312

6.  Sarcomas and sarcomatoid neoplasms of the major salivary gland regions. A clinicopathologic and immunohistochemical study of 67 cases and review of the literature.

Authors:  P L Auclair; J M Langloss; S W Weiss; R L Corio
Journal:  Cancer       Date:  1986-09-15       Impact factor: 6.860

Review 7.  Sarcomas of the head and neck region.

Authors:  Erich M Sturgis; Bryan O Potter
Journal:  Curr Opin Oncol       Date:  2003-05       Impact factor: 3.645

8.  ERG expression in epithelioid sarcoma: a diagnostic pitfall.

Authors:  Markku Miettinen; Zengfeng Wang; Maarit Sarlomo-Rikala; Ziedulla Abdullaev; Svetlana D Pack; John F Fetsch
Journal:  Am J Surg Pathol       Date:  2013-10       Impact factor: 6.394

Review 9.  Undifferentiated tumor: true identity by immunohistochemistry.

Authors:  Armita Bahrami; Luan D Truong; Jae Y Ro
Journal:  Arch Pathol Lab Med       Date:  2008-03       Impact factor: 5.534

Review 10.  Primary sarcomas of the salivary glands: case series and literature review.

Authors:  Cara C Cockerill; Shiva Daram; Adel K El-Naggar; Ehab Y Hanna; Randal S Weber; Michael E Kupferman
Journal:  Head Neck       Date:  2013-06-01       Impact factor: 3.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.